Fig. 1: Distinct chemokine autoantibodies correlate with SARS-CoV-2 infection, favorable disease outcomes and lack of long COVID. | Nature Immunology

Fig. 1: Distinct chemokine autoantibodies correlate with SARS-CoV-2 infection, favorable disease outcomes and lack of long COVID.

From: The kinetics of chemokine autoantibodies in COVID-19

Fig. 1

Muri et al.4 show that chemokine autoantibodies are widespread after SARS-CoV-2 infection. The ‘COVID-19 signature’ (autoantibodies to CXCL17, CCL19 and CCL22; left panel) is elevated in SARS-CoV-2-infected individuals compared with that in uninfected controls, and might block the migration of T cells, B cells and dendritic cells (DCs) into the tissue. The ‘hospitalization signature’ (autoantibodies to CXCL5, CXCL8 and CCL25; middle panel) is found in outpatients, and might block the migration of neutrophils, monocytes, DCs and T cells into the tissue. The ‘long COVID signature’ (autoantibodies to CXCL13, CXCL16 and CCL21; right panel) is higher in people without long COVID, and might block the migration of T cells, B cells and DCs into the tissue.

Back to article page